InterVenn Biosciences vs Karius
Side-by-side comparison of AI visibility scores, market position, and capabilities
InterVenn Biosciences pioneered clinical glycoproteomics with AI-powered liquid biopsy diagnostics for cancer; raised $251M total, received AMA PLA code for non-invasive ovarian cancer test in July 2025.
About
InterVenn Biosciences is a clinical-stage diagnostics company that has pioneered the field of glycoproteomics — the study of proteins modified with sugar molecules (glycans) — combined with artificial intelligence to develop next-generation liquid biopsy tests for cancer detection and treatment monitoring. The company's VOCAL test provides a non-invasive diagnostic for ovarian cancer using a blood draw, and its GlycoKnowPR platform delivers glycoproteomic immunotherapy response assays to help oncologists predict how patients will respond to treatment before administering therapy.
Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.
About
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.